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Background: Carbon nanotubes have shown broad potential in biomedical  applications, given 
their unique mechanical, optical, and chemical properties. In this pilot study, carbon nanotubes 
have been explored as multimodal drug delivery vectors that facilitate antiangiogenic therapy 
in zebrafish embryos.
Methods: Three different agents, ie, an antiangiogenic binding site (cyclic arginine-glycine-
aspartic acid), an antiangiogenic drug (thalidomide), and a tracking dye (rhodamine), were 
conjugated onto single-walled carbon nanotubes (SWCNT). The biodistribution, efficacy, and 
biocompatibility of these triple functionalized SWCNT were tested in mammalian cells and 
validated in transparent zebrafish embryos.
Results: Accumulation of SWCNT-associated nanoconjugates in blastoderm cells facilitated 
drug delivery applications. Mammalian cell xenograft assays demonstrated that these antian-
giogenic SWCNT nanoconjugates specifically inhibited ectopic angiogenesis in the engrafted 
zebrafish embryos.
Conclusion: This study highlights the potential of using SWCNT for generating efficient 
nanotherapeutics.
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Introduction
Tumor angiogenesis is an essential step in tumor progression and metastasis formation, 
and also provides important targets for tumor diagnosis and therapy. Antiangiogenic 
strategies have been pursued for cancer treatment and prevention of cancer recur-
rence and metastasis.1,2 A variety of antiangiogenic agents, which lead to inhibition 
of angiogenesis, such as platelet factor 4, angiostatin, endostatin, and vasostatin, are 
already in the clinical trials.3 However, antiangiogenic therapies usually have toxic 
side effects without specific targeting. Molecules associated with angiogenesis are 
now being considered as attractive targets for inhibition of angiogenesis. Recent 
evidence indicates that vascular integrins, in particular alpha-v-beta-3 (α
v
β
3
), are 
important regulators of angiogenesis, including tumor angiogenesis. Integrin α
v
β
3
 is 
highly expressed on activated endothelial and tumor cells, but is not present in resting 
endothelial cells and most normal organ systems. This property makes it a suitable 
target for antiangiogenic cancer therapy.2 The cyclic arginine-glycine-aspartic (RGD) 
peptide recognizes α
v
β
3
 integrin receptors and has been widely used for detection of 
α
v
β
3
 expression.4,5
Carbon nanotubes are a potential and promising vector for drug delivery, with 
a relatively long blood circulation time and intrinsic transporting ability.6 Carbon 
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nanotube-biomolecule nanoconjugates have been used in 
proof-of-principle experiments to demonstrate targeting to 
desired cell populations for immune recognition or to achieve 
therapeutic effects.7,8 In a pilot study that assessed the interac-
tions of carbon nanotubes in zebrafish embryos, we found 
that carbon nanotubes are distributed in the blastoderm cells, 
but not in the yolk.9 This property facilitates effective drug 
delivery in zebrafish because most of the important events 
occur in the blastoderm cells. Furthermore, carbon nanotubes 
can be distributed by blood flow throughout the whole car-
diovascular system in transparent zebrafish embryos.9
Embryonic circulation and development of blood ves-
sels have been studied in detail in the zebrafish.10 Zebrafish 
embryos are transparent, which facilitates visual inspection 
of the cardiovascular system as well as changes in blood 
vessel growth. At 24 hours following fertilization, the major 
vessels, aorta (dorsal artery), and posterior cardial vein are 
formed. These major vessels are formed by the process of 
vasculogenesis.11 The whole vasculature is established by 
72 hours following fertilization.12 Furthermore, the forma-
tion of zebrafish blood vessels by angiogenic sprouting 
appears to require the same proteins shown to be necessary 
for blood vessel growth in mammals.13 The pattern of blood 
vessel development is almost the same between individual 
embryos.14
In zebrafish embryos, subintestinal vessels originate from 
the duct of the Cuvier at 48 hours following fertilization, and 
these vessels supply the digestive system. At 24–48 hours 
following fertilization, the subintestinal vessels form a 
vascular plexus by angiogenesis across most of the dorsal-
lateral aspect of the yolk ball,10 and the plexus is apparent 
by 72 hours following fertilization.15 Because the vascular 
plexus of the subintestinal vessels can be seen, it has been 
widely used as a structural parameter for determination of 
either pharmacological angiogenesis or inhibition of the 
angiogenesis process. Defects in the development of the 
zebrafish embryo vascular system can be visualized and 
recorded by live imaging analysis using either microangiog-
raphy or transgenic zebrafish embryos.
In the present study, we used transparent zebrafish 
embryos and functionalized carbon nanotubes to study nano-
therapeutics in angiogenesis. Single-walled carbon nanotubes 
(SWCNT) were conjugated with three different agents for 
multimodal drug delivery. The conjugated agents included 
the antiangiogenesis drug, thalidomide, a peptide cyclic RGD 
for angiogenesis-specific targeting, and a fluorescent marker 
at noncompeting binding sites. Thalidomide was chosen as an 
antiangiogenesis therapeutic agent because it is a widely used 
anticancer drug for the treatment of many cancers.16,17 Cyclic 
RGD peptides recognize angiogenesis, and are a marker for 
the identification of angiogenesis in many cancer models.4,5 
The fluorescent marker, rhodamine (Rh), allows the tracking 
of SWCNT inside mammalian cells and zebrafish embryos 
under confocal microscopy. The biodistribution and ectopic 
angiogenesis-targeting efficacy of triple-coated SWCNT 
were investigated in zebrafish embryos. The targeted anti-
angiogenesis therapy was then studied in a zebrafish tumor 
xenograft angiogenesis assay.
Materials and methods
Thalidomide analogs and SWCNT 
conjugates
SWCNT were purchased from Nanostructured and 
Amorphous Materials Inc (Houston, TX). Thalidomide, 
polyoxyethylene bis(amine) (NH
2
-PEG-NH
2
, with an 
molecular weight of 3350), N-hydroxy succinimide (NHS) 
and N-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC) were purchased from Sigma-Aldrich 
(St Louis, MO). 2-(Boc-amino) ethyl bromide was purchased 
from Fluka. NHS-Rh, succinimidyl 4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (SMCC), and N-succinimidyl 
S-acetylthioacetate (SATA) were purchased from Pierce 
(Rockford, IL). Unless specified, the chemicals and reagents 
were used as received from the relevant commercial sources. 
A Microcon centrifugal filter device (YM-100, regenerated 
cellulose 10,000 molecular weight cutoff) was purchased 
from Millipore (Billerica, MA). A Spectra/Por® dialysis 
membrane (molecular weight 12,000–14,000) was purchased 
from Spectralabs (Rancho Dominguez, CA).
Thalidomide was first modified with 2-(Boc-amino) ethyl 
bromide to generate the amino group, and then the compound 
was conjugated with SATA to yield the thiolated thalidomide 
(denoted as thalidomide-SH). The experimental details for 
the synthesis of thalidomide analogs can be found in the 
Supplementary Materials section.
The raw SWCNT were first oxidized to obtain oxidized 
SWCNT, and then the oxidized SWCNT were conjugated 
with polyethylene glycol (PEG) to yield PEGylated SWCNT. 
The PEGylated SWCNT were labeled with NHS-Rh and 
fluorescein isothiocyanate (FITC) to generate Rh-labeled 
SWCNT (Rh-SWCNT) and FITC-SWCNT, respectively. 
The RGD-SH was synthesized by Dr Cong Li from the 
School of Pharmacy at Fudan University (Shanghai, China). 
The FITC-SWCNT were first reacted with SMCC to pro-
duce FITC-SWCNT-SMCC, and then further reacted with 
RGD-SH in the presence of 10 mM Tris(2-carboxyethyl) 
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phosphine hydrochloride (TCEP) at pH 7.4 to yield FITC-
SWCNT-RGD. Rh-SWCNT was also firstly reacted with 
SMCC to produce Rh-SWCNT-SMCC, and Rh-SWCNT-
SMCC conjugates were reacted overnight with RGD-SH 
and thalidomide-SH in the presence of 10 mM TCEP at 
pH 7.4 to obtain RGD-SWCNT(Rh)-thalidomide and Rh-
SWCNT-RGD conjugates. The molar ratio of RGD-SH to 
thalidomide-SH is 1:5. Because the effective concentration 
of thalidomide is higher than that of RGD, a combination 
of a high ratio of thalidomide and low ratio of RGD was 
adopted in the study. The concentration of thalidomide 
loaded onto the SWCNT was measured by the absorbance 
peak at 299 nm (characteristic of thalidomide). The detailed 
synthesis procedures and characterization measurement 
information of all SWCNT-based conjugates can be found 
in the Supplementary Materials section. All SWCNT-based 
conjugates were dissolved in 1× phosphate-buffered saline 
for related biological experiments.
1H nuclear magnetic resonance (NMR) spectra were mea-
sured on a Varian 300 or Varian 400-MR spectrometer (Agilent 
Technologies, Inc, Santa Clara, CA). Electrospray ionization 
(ESI) mass spectroscopic (MS) data were determined with 
a ThermoFinnigan LCQTM (Thermo Scientific, Waltham, 
MA) electrospray ionization mass spectrometer. Ultraviolet-
visible spectra were recorded on a Thermo Spectronic UV1 
spectrometer. The morphologies and structures of SWCNT 
and RGD-SWCNT(Rh)-thalidomide conjugates were 
characterized by transmission electron microscopy (TEM, 
Tecnai 20; Philips, Amsterdam, the Netherlands) with an 
accelerating voltage of 200 kV. The samples were prepared 
by drying droplets of a sample in ethanol dispersed onto 
carbon-coated copper grids. The purity of PEG-modified 
SWCNT was estimated by thermogravimetric analysis, which 
was performed on a Pyris-1 (Perkin Elmer, Waltham, MA) 
sphere thermal analysis system under flowing air at a scan 
rate of 20°C/minute from 50°C to 800°C.
Human cell culture experiments
The four mammalian cancer cell lines used in this study 
were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA), namely, human glioblastoma cancer 
cells U87MG (ATCC HTB-14), human breast cancer cells 
MCF-7 (ATCC HTB-22), ovarian SKOV3 carcinoma cells 
(ATCC HTB-77), and human HT1080 fibrosarcoma cells 
(ATCC CCL-121). Integrin α
v
β
3
-positive cells (U87MG) and 
integrin α
v
β
3
-negative cells (MCF7) were used to study the 
targeting efficacy of RGD-labeled SWCNT. Ovarian SKOV3 
carcinoma cells which carried a plasmid-expressing enhanced 
green fluorescent protein (pEGFP; SKOV3:pEGFP) was used 
to establish the zebrafish xenograft assay. Human HT1080 
fibrosarcoma cells, the proangiogenic mammalian tumor cells, 
were used for induction of ectopic angiogenesis in the zebrafish 
cancer model. The cells were cultured in Dulbecco’s modified 
Eagle’s medium (Invitrogen, San Diego, CA). The media were 
supplemented with 10% fetal bovine serum (Invitrogen), 
100 U penicillin, and 10 µg/mL streptomycin (Invitrogen) in 
5% CO
2
, in 95% air at 37°C in a humidified incubator. After 
incubating the cells with FITC-SWCNT or FITC-SWCNT-
RGD at 37°C (CO
2
 5%) for 3–4 hours, the cells were rinsed 
with fresh culture medium and imaged by a Leica confocal 
laser scanning microscope (SPE or SP5; Leica Camera AG, 
Solms, Germany) combination system equipped with a Plan-
Neofluar 40 × 1.3 NA oil DIC objective.
Maintenance of zebrafish
Friend leukemia integration 1a (fli1a) is a transcription fac-
tor constitutively expressed in endothelial cells. Transgenic 
fli1a:EGFP zebrafish containing fluorescently labeled 
endothelial cells were used to study the experimental antian-
giogenic therapy in vivo. Generation and characterization of 
the fli1a:EGFP lines has been described in detail in the litera-
ture.18 In transgenic zebrafish, the promoter of the endothelial 
marker, fli1a, drives the expression of EGFP in the blood 
vessels. The formation of the embryonic vasculature can be 
visualized in the transgenic fli1a:EGFP zebrafish as well.
Wild-type mature zebrafish (Danio rerio) were purchased 
from a local commercial source (Chong Hing Aquarium, 
Hong Kong, China). The transgenic fli1a:EGFP zebrafish 
were purchased from Zebrafish International Resource 
Center (Eugene, OR). The zebrafish colony was maintained 
as previously described.19 Adult zebrafish were maintained 
in charcoal-filtered tap water supplemented with salts and 
kept in 14-hour light: 10-hour dark cycles. The embryos were 
obtained by photoinduced spawning over green plants and 
cultured at 28.5°C in filtered tap water. The developmental 
stage of the embryos was measured according to the number 
of hours following fertilization and staged according to a 
method described elsewhere.20
Injection of SWCNT into zebrafish 
embryos to study biodistribution
The fluorescent Rh-SWCNT and Rh-SWCNT-RGD were 
loaded into the cell of wild-type zebrafish embryos by micro-
injection at the one-cell stage to study in vivo biodistribution. 
After the light was turned on for photoinduced spawning, the 
embryos were collected within 15 minutes after fertilization 
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and selected under a dissecting microscope for microinjection 
for the one-cell stage experiments. Zebrafish embryos were 
collected into a microinjection plate filled with incubation 
medium. The Rh-SWCNT or Rh-SWCNT-RGD was then 
injected into the embryonic cell or yolk of the embryos with a 
nitrogen-driven microinjector (Narishige) within 45  minutes 
of fertilization. After microinjection, the embryos were 
incubated at 28.5°C for further development and imaged 
on a Olympus Disk Scanning Unit (DSU, Olympus, Tokyo, 
Japan) using internal DSU filter CY3 cubes at critical time 
points. Wild-type zebrafish embryos from the same clutch 
that were not injected were used as controls. All embryos 
were cultured in embryo medium which contained 0.2 mM 
1-phenyl-2-thiourea (PTU) from 24 hours following fertiliza-
tion to inhibit pigment development.
Zebrafish wound healing model
The fluorescent dye-labeled Rh-SWCNT-RGD was loaded 
into the yolk of transgenic fli1a:EGFP zebrafish embryos 
by microinjection at the one-cell stage as described above. 
Transgenic zebrafish embryos from the same clutch that were 
not injected were used as controls. To study angiogenesis 
targeting through the use of RGD-SWCNT nanoconjugates, 
a zebrafish wound healing model was adopted for this study. 
At 48 hours following fertilization, 20 embryos were anes-
thetized with 0.016% (w/v) tricaine (ethyl 3-aminobenzoate 
methanesulfonate, Sigma-Aldrich). The wound site was then 
generated on the trunk area of the embryos using the tip 
of a pair of forceps, without destruction of the circulatory 
system. At 72 hours following fertilization, the embryos 
were assessed under DSU using internal DSU filters GFP 
and CY3 cubes.
Antiangiogenic activity of thalidomide-
SWCNT conjugates
Transgenic fli1a:EGFP zebrafish embryos were used to study 
the antiangiogenic activity of thalidomide and its conjugates. 
Thalidomide was dissolved in dimethyl sulfoxide to make up 
a 400 mM stock solution. To make the stock solution, thalido-
mide in dimethyl sulfoxide was heated for 2 minutes at 65°C 
and shaken vigorously for 2 minutes at room temperature, and 
repeated more than ten times. A higher concentration of thali-
domide stock was required to keep the final concentration of 
dimethyl sulfoxide under 0.1% in the exposure experiments. 
The thiolated thalidomide and thalidomide-SWCNT were 
dissolved in water. Twenty transgenic fli1a:EGFP zebrafish 
embryos at 4 hours following fertilization were placed into 
2.5 mL of dosing solution that contained 0.2 mM PTU and 
allowed to develop at 28.5°C. The treated embryos were 
assessed at 48 hours following fertilization under a confocal 
microscope. The embryos were anesthetized in 0.016% (w/v) 
tricaine prior to observations.
Xenograft angiogenesis assay  
in zebrafish embryos
The method of xenograft angiogenesis assay in zebrafish 
embryos was used to study the therapeutic effect of syn-
thesized nanotherapeutics. Both wild-type and transgenic 
fli1a:EGFP zebrafish were used in the xenograft angiogenesis 
assay. Wild-type zebrafish embryos were xenografted with 
ovarian SKOV3 carcinoma cells which carried a pEGFP 
(SKOV3:pEGFP) with nanoconjugates to establish the assay. 
Transgenic fli1a:EGFP zebrafish embryos were xenografted 
with human fibrosarcoma cells HT1080 with or without 
nanoconjugates to study the therapeutic effects.
Existing procedures for xenograft angiogenesis assay 
in zebrafish embryos were adopted21 with some modifica-
tions. At 4 hours following fertilization, the embryos were 
examined under a dissecting microscope, and only embryos 
that developed normally and reached the blastula stage were 
selected for subsequent experiments. All selected embryos 
were cultured in embryo medium that contained 0.2 mM PTU, 
starting from 24 hours following fertilization. At 48 hours 
following fertilization, the zebrafish embryos were dechori-
onated and then anesthetized using 0.016% (w/v) tricaine. 
The anesthetized zebrafish embryos were laterally mounted 
in a 0.3% agarose-coated Petri dish covered with embryo 
culture medium, and the embryos were orientated with the 
yolk on a flank. The orientated embryos were injected with 
1000–2000 mammalian cancer cells per embryo and resus-
pended in 3–4 nL of Matrigel (Becton Dickinson, Franklin 
Lakes, NJ) using a Picospritzer microinjector (Eppendorf, 
Hamburg, Germany). The pipette was calibrated every time 
before microinjection. The calibration of the microinjection 
pipette was performed by injecting the solution into mineral 
oil and quantifying the volume. Injection of the same volume 
of Matrigel solution was used as the negative control. The 
detailed protocol for cell injection has been described in 
the literature.21 In each experiment, a total of 15 embryos 
were injected with Matrigel only, HT1080 cells only, and 
both HT1080 cells and RGD-SWCNT(Rh)-thalidomide 
(1.2 mg/mL of SWCNT, with 0.334 mg/mg thalidomide and 
0.125 mg/mg RGD on SWCNT), respectively. The experi-
ments were repeated separately four times.
After injection, the embryos were incubated in embryo 
medium containing 0.2 mM PTU for another 24 hours 
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before imaging. The embryos were imaged live at 72 hours 
following fertilization by a Leica confocal laser scanning 
microscope (SPE or SP5) combination system equipped 
with a Plan-Neofluar 40 × 1.3 NA oil DIC objective. The 
images were then further processed for scoring of vascular 
changes and quantification analysis of subintestinal vessel 
formation. The embryos were anesthetized in 0.016% (w/v) 
tricaine prior to observation.
Vascular changes and subintestinal  
vessel formation
The subintestinal vessels form on the dorsolateral surface 
of the yolk on both sides of the embryo in the shape of 
a basket over the yolk.12 In this study, proangiogenic or 
antiangiogenic effects are defined as either a gain or loss of 
either the lateral or ventral vessel of the basket. In order to 
compare the effects of different treatments on angiogenesis, 
we quantified vessel formation. The subintestinal vessels in 
the transgenic fli1a:EGFP zebrafish were visualized under 
confocal microscopy. A quantitative analysis was performed 
on a PC computer using the public domain NIH Image 
program (developed at the US National Institutes of Health 
and publicly available on the Internet at http://rsb.info.nih.
gov/nih-image/). Using this software, the overall length of 
the subintestinal vessels was quantified by manual point to 
point measurement, and the area of the subintestinal vessels 
was quantified in a similar way.
Results
Synthesis and characterization of RGD-
SWCNT(Rh)-thalidomide nanoconjugates
To evaluate the targeting and efficacy of the SWCNT-
based drug delivery system, we designed and synthesized 
fluorescently-labeled SWCNT conjugates. The fluorescent 
dye-labeled SWCNT, FITC-SWCNT, and FITC-SWCNT-
RGD were used to track the internalization of PEGylated 
SWCNT and SWCNT-RGD, respectively, in the tumor 
cells. Fluorescence Rh-labeled SWCNT conjugates, Rh-
SWCNT, Rh-SWCNT-RGD, and RGD-SWCNT(Rh)-
thalidomide were designed as fluorescent molecular 
probes for the SWCNT-based conjugates for tracking the 
biodistribution of SWCNT and drug release in zebrafish 
embryos.
To couple thalidomide with SWCNT, thalidomide 1 was 
initially coupled with 2-(Boc-amino) ethyl bromide in the 
presence of sodium hydride and dimethylformamide (DMF) 
to form thalidomide 2 (Figure S1, Supplementary materials). 
A free sulfhydryl group was then grafted to  thalidomide 2 
through modification with the  heterobifunctional linker, 
SATA, followed by reaction with hydroxylamine. The 
 thalidomide derivatives were structurally characterized 
by ultraviolet-visible spectroscopy, 1H nuclear magnetic 
 resonance (NMR) and ESI-MS (detailed in the  Supplementary 
materials section).
The synthesis of SWCNT-based conjugates is illustrated 
in Figure 1 and the Supplementary Materials section. Raw 
SWCNT were first functionalized and purified by oxidation 
in concentrated HNO
3
 to obtain SWCNT 2. The ends and 
defect sites on the side wall of the oxidized SWCNT were 
functionalized with carboxylic acid and carboxylate groups, 
which have been summarized in a previous review.22 These 
carboxylic acid and carboxylate groups were subsequently 
reacted with amine moieties through carbodiimide-activated 
coupling with diamine-terminated PEG (PEG
3500N
) to give 
PEGylated SWCNT 3. The TEM image of raw SWCNT is 
shown in Figure 2A. The average diameter of SWCNT is 
about 1–2 nm. The length of the SWCNT in the raw sample 
was 5–30 µm. However, the majority of the SWCNT were 
found to be 100–800 nm in length, with a mean length of 
200 nm after oxidation and modification, as statistically 
estimated by TEM images. In addition, the purity of PEG-
modified SWCNT was characterized by thermogravimetric 
analysis. Figure 2B shows the thermogravimetric analysis 
curves from H
2
N-PEG-NH
2
, raw SWCNT, and SWCNT-
PEG-NH
2
. Upon heating in air, all species that were pres-
ent in the SWCNT were converted to their corresponding 
oxides. The H
2
N-PEG-NH
2
 started to decompose at 200°C, 
and 95% of the H
2
N-PEG-NH
2
 was decomposed at 400°C 
(dashed line). It is also seen that the mass of raw SWCNT 
quickly decreased at 500°C (dotted line). There was still 
15.9% of the residual weight after thermal decomposition. 
In contrast, the thermogravimetric analysis measurement 
of SWCNT-PEG-NH
2
 (solid line) showed two main large 
bands in the weight percent decrease curve. Assuming that 
the mass loss occurring during the first thermal decomposi-
tion of the SWCNT-PEG-NH
2
 sample was due entirely to the 
removal of the H
2
N-PEG-NH
2
, the residual weight after the 
first decomposition (80%) implies a SWCNT content as high 
as 20%. The residual weight after the second decomposition 
is about 0.07%, which indicates high purity of SWCNT after 
oxidation and modification.
The amount of reactive amine group on PEG-modified 
SWCNT was estimated to be 2.8 × 10−6 mol/mg, which was 
measured by quantifying pyridine-2-thion following reac-
tion with N-succinimidyl 3-(2-pyridyldithio) propionate 
(SPDP).23,24 The fluorescent Rh molecule was reacted with 
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amine to obtain Rh-SWCNT 4. The amount of Rh on the 
SWCNT was about 0.4 0 × 10−6 mol/mg, determined by mea-
suring the free amine groups on SWCNT after conjugation 
with Rh. SMCC was then reacted with the remaining amine 
to provide a linker to conjugated RGD and thalidomide to 
yield the desired nanoconjugates, ie, Rh-SWCNT-RGD and 
RGD-SWCNT(Rh)-thalidomide. The unconjugated RGD 
and thalidomide were thoroughly removed from the RGD-
SWCNT(Rh)-thalidomide and Rh-SWCNT-RGD solution 
using a 10,000 Dalton centrifugal device. All SWCNT-based 
nanoconjugates were quite soluble in an aqueous medium, 
which was attributed to the high density of the hydrophilic 
glycol chains on the surface of the SWCNT. Distinct peaks 
in the ultraviolet-visible spectrum for thalidomide and Rh 
are shown in Figure 2C. Absorption peaks at 520 nm and 
552 nm confirm the presence of Rh in these conjugates. 
The peak at about 290 nm can be mainly attributed to tha-
lidomide molecules. After subtraction of the contribution 
of SWCNT to the absorbance, the amount of thalidomide 
on the SWCNT was evaluated to be 0.334 mg/mg.
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Figure 1 Synthesis route of RGD-SWCNT(Rh)-thalidomide conjugates. (a) HNO3, 24 hours; (b) H2N-PEG-NH2, EDC, NHS, 0.1 M PBS, pH 7.4; (c) NHS-Rh, DMF; (d) 
SMCC, DMSO; (e) RGD-SH, thalidomide-SH. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-walled carbon nanotubes; Rh, rhodamine; PEG, polyethylene glycol; EDC, N-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; NHS, N-hydroxy succinimide; PBS, phosphate-buffered saline; DMF, dimethylformamide; SMCC, succinimidyl 
4-[N-maleimidomethyl]cyclohexane-1-carboxylate; DMSO, dimethyl sulfoxide.
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Figure 2 (A) Transmission electron microscopy images of pristine SWCNT; (B) thermogravimetric analysis curves of H2N-PEG-NH2 (dashed line), raw SWCNT (dotted 
line), and SWCNT-PEG-NH2 (solid line) under air which show the sequential loss of H2N-PEG-NH2 and SWCNT; (C) ultraviolet-visible absorbance spectra of PEGylated 
SWCNT, Rh, thalidomide, and RGD-SWCNT(Rh)-thalidomide conjugate 6 in H2O. The absorbance peak of thalidomide at 299 nm was used to measure the thalidomide 
loading on carbon nanotubes. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-walled carbon nanotubes; Rh, rhodamine; PEG, polyethylene glycol.
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In vitro angiogenesis inhibition using 
FITC-SWCNT-RGD
In order to study the penetration properties of PEGylated 
SWCNT, we also synthesized FITC-labeled SWCNT con-
jugates, including FITC-SWCNT and FITC-SWCNT-RGD 
(Figure S2, Supplementary Materials). The integrin α
v
β
3
-
positive cells (U87MG) and integrin α
v
β
3
-negative cells 
(MCF7) were incubated with FITC-SWCNT (0.12 mg/mL 
of SWCNT, and 0.45 × 10−7 mol/mg of FITC on SWCNT), 
respectively. After 4 hours of coincubation, the fluorescence 
of exposed live cells was detected by confocal microscopy. It 
was found that a much higher fluorescent signal is observed 
in MCF7 cells, whereas little fluorescence is observed in 
U87MG cells. Since the cytomembrane is impermeable to 
FITC,7 the high fluorescence signals in Figure 3A correspond 
to the FITC labeled on the SWCNT taken up by MCF7 cells. 
The fluorescence intensity was measured and analyzed using 
MetaMorph (Universal Imaging, Downingtown, PA). The 
relative fluorescent intensity from the intracellular FITC-
SWCNT in the MCF7 cells (Figure 3A) was 3.4 times 
stronger than that in the U87MG cells (Figure 3D). This 
result indicates that, at the same dose and exposure condi-
tions, FITC-SWCNT have a higher affinity for MCF7 cells 
than for U87MG cells.
We then studied the targeting efficiency of FITC-
SWCNT-RGD to U87MG and MCF-7 cells further. After 
incubation with FITC-SWCNT-RGD (0.12 mg/mL of 
SWCNT, 12.5 µg/mg RGD, and 0.45 × 10–7 mol/mg of FITC 
on SWCNT) for 3 hours, the U87MG cells began to show a 
growth inhibition effect while MCF7 was little affected, as 
indicated by their morphological changes shown in  Figure 3C 
and F. Furthermore, a much higher fluorescence signal was 
observed in the U87MG cells and little fluorescence signal 
was observed in the MCF7 cells. The relative fluorescent 
intensity from the intracellular FITC-SWCNT-RGD in the 
MCF7 cells (Figure 3B) is only 58% of that in the U87MG 
cells (Figure 3E). Due to the low integrin α
v
β
3
 expression 
in the MCF7 cells, very low levels of FITC-SWCNT-RGD 
in the MCF7 cells was observed. With a high integrin α
v
β
3
 
expression in the U87MG cells, FITC-SWCNT-RGD can 
selectively recognize U87MG cells with RGD, and afford 
little destruction of integrin α
v
β
3
-negative cancer and nor-
mal cells. Considering the high affinity of SWCNT-FITC 
to MCF7 cells, these results show that FITC-SWCNT-RGD 
affords efficient angiogenesis targeting in vitro.
Biodistribution of Rh-SWCNT-RGD  
in zebrafish embryos
Zebrafish embryos loaded with PEGylated SWCNT at the 
one-cell stage developed normally to the larval stage (data not 
shown), in which embryos loaded with multiwalled carbon 
nanotubes showed a similar effect.9 After being introduced 
Figure 3 Confocal microscopic images of MCF7 cells (A, B and C) and U87MG cells (D, E and F) incubated with FITC-SWCNT (A and D) and FITC-SWCNT-RGD 
(B, C, E and F). (A) and (F) are the bright view images of (B) and (E), respectively. The green fluorescent signals indicate the location of FITC-SWCNT (A and D) and 
FITC-SWCNT-RGD (B and E) in the cells. Scale bar: 25 µm. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-walled carbon nanotubes; FITC, fluorescein isothiocyanate.
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into embryonic cells at the one-cell stage, the Rh-SWCNT were 
allocated to all the blastoderm cells but not the yolk through 
cell division (data not shown). In order to determine whether 
the conjugation of RGD affects biodistribution, Rh-SWCNT-
RGD were introduced into zebrafish embryos at the one-cell 
stage by microinjection. About 2.4 ng of SWCNT and 0.3 ng 
of RGD were loaded into the injected embryos, with an injec-
tion volume of about 2 nL. The biodistribution profiles of Rh-
SWCNT-RGD were time lapse-imaged by DSU microscopy 
at several important time points in live zebrafish embryos, and 
the representative images are shown in Figure 4. It was found 
that Rh-SWCNT-RGD displays a similar biodistribution pattern 
as Rh-SWCNT, with a dominant blastoderm cell distribution. 
Loaded Rh-SWCNT-RGD were excluded from the yolk, even 
though there were frequent exchanges between the blasto-
derm cells and the yolk during embryonic development. The 
dominant blastoderm cell distribution of Rh-SWCNT-RGD 
implies effective drug delivery in zebrafish given that most of 
the important events occur in the blastoderm cells.
Angiogenesis targeting by RGD-SWCNT 
nanoconjugates
In this study, a wound healing-associated angiogenesis 
model was used to study the angiogenesis-targeting ability 
of Rh-SWCNT-RGD. Angiogenesis, the growth of new blood 
vessels, is an important natural process required for wound 
healing and restoring blood flow to tissues after an injury or 
insult. Immediately following an injury, angiogenesis is initi-
ated by multiple molecular signals.25 During angiogenesis, 
both structural and inflammatory cells in different tissues are 
involved in the mechanisms of endothelial cell proliferation, 
migration, and activation, through the production and release 
of angiogenic mediators.26
The zebrafish wound site was generated at 24 hours follow-
ing fertilization, but the recovery process was so fast during 
early development that the embryos were able to recover totally 
from the wound without leaving any scars for identification 
(data not shown). When the wound site was generated at 
48 hours following fertilization, 20 treated embryos all showed 
a scar structure on the trunk at 72 hours following fertilization. 
As shown in Figure 5A, the wound site is marked in the red 
boxed area, and the FITC channel (Figure 5C) clearly shows 
angiogenesis in the wound site. In the Rh channel (Figure 5B), 
an accumulated yellow signal is observed in the wound site, 
which indicates specific targeting of Rh-labeled RGD-SWCNT. 
Because integrin α
v
β
3
 is also overexpressed on the activated 
endothelial cells during wound healing,27 the effective integrin 
α
v
β
3
-targeting ability of RGD serves as a valuable marker of 
angiogenesis after ischemic injury, myocardial infarction, 
and inflammation. In this study, RGD-SWCNT conjugates 
preserved the specific angiogenesis-targeting ability after 
72 hours of loading inside the zebrafish, which indicates that 
the nanoconjugates help to prevent degradation of cyclic RGD 
peptide and preserves its activity in vivo. After being distributed 
inside the embryos for 72 hours, the RGD-SWCNT conjugates 
can still move towards the targeted site and thus allow detec-
tion of the distinct proangiogenesis signal generated from the 
wound healing process which is different from other sites with 
a novel level of angiogenesis. In contrast with loading into the 
embryonic cell at the one-cell stage, a certain amount of the 
loaded SWCNT remains inside the yolk part, although quite 
a large portion of the loaded SWNCT is allocated to the blas-
toderm cells, as indicated by the yellow signal in Figure 5B. 
Another two of the untreated fli1a:EGFP zebrafish larvae show 
a normal morphology of the trunk part without any wounds, 
and the GFP fluorescent channel demonstrates the blood vessel 
system in normal embryos.
Angiogenesis inhibition by thalidomide-
SWCNT nanoconjugates
Thalidomide-induced antiangiogenic activity was confirmed 
in the zebrafish embryos. The lowest effective concentration 
of thalidomide in the zebrafish embryos was 2 mg/mL. After 
Figure 4 In vivo biodistribution of Rh-SWCNT-RGD in developing zebrafish 
embryos at different developmental stages. Zebrafish embryos were loaded with 
2 nL of Rh-SWCNT-RGD (2.4 ng of SWCNT and 0.3 ng of RGD) into embryonic 
cells at the one-cell stage through microinjection. According to the red fluorescence 
signal from Rh-SWCNT-RGD, the loaded Rh-SWCNT-RGD are distributed into 
the blastoderm cells, but not the yolk cells, at all observed developmental stages, 
including the four-cell stage (A), 3 hours following fertilization (B), 8 hours following 
fertilization (C), and 28 hours following fertilization (D). Scale bar: 200 µm.
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-
walled carbon nanotubes; Rh, rhodamine.
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modification, thiolated thalidomide demonstrated antian-
giogenic activity at a relatively lower concentration, and 
the lowest effective concentration of thiolated thalidomide 
was about 0.4 mg/mL. To determine whether thalidomide-
SWCNT have similar effects on the zebrafish embryos, 
the zebrafish embryos were treated with 0.334 mg/mg 
thalidomide-SWCNT (SWCNT concentration 1.2 mg/mL). 
The effects of thalidomide on angiogenic vessel formation 
was assessed using transgenic fli1a:EGFP zebrafish embryos. 
Blood vessel patterning is highly characteristic in develop-
ing zebrafish embryos, and intersegmental blood vessels can 
be easily  visualized microscopically by imaging transgenic 
fli1a:EGFP zebrafish that contain fluorescently-labeled 
endothelial cells. Treatment with 0.334 mg/mg thalidomide-
SWCNT (1.2 mg/mL of SWCNT) for 44 hours showed 
inhibition of intersegmental blood vessel formation in 
zebrafish embryos, as observed under a confocal microscope 
(Figure 6). In the control group, one embryo showed both 
Figure 5 In vivo angiogenesis targeting of Rh-SWCNT-RGD in zebrafish wound 
healing model. By imaging transgenic fli1a:EGFP zebrafish that contained fluorescently-
labeled endothelial cells, angiogenesis associated with wound healing in transgenic 
zebrafish embryos can be observed by checking the GFP signal. (A) Bright view 
and (B) Rh channel. Red fluorescence indicates the location of Rh-SWCNT-RGD 
in the zebrafish embryos. (C) indicates the FITC channel. Green fluorescence 
indicates distribution of fluorescently-labeled endothelial cells in transgenic zebrafish 
embryos. The red boxed area marks the region with a wound. The green boxed area 
marks a normal region in the zebrafish trunk. Scale bar: 150 µm. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-
walled carbon nanotubes; Rh, rhodamine; FITC, fluorescein isothiocyanate; EGFP, 
enhanced green fluorescent protein.
Figure 6 Inhibitory effects of SWCNT-conjugated thalidomide on angiogenesis in 
transgenic zebrafish embryos. Transgenic fli1a:EGFP zebrafish embryos were treated 
with 0.334 mg/mg thalidomide-SWCNT (thalidomide concentration, 1.2 mg/mL of 
SWCNT) from 4 hours following fertilization to 48 hours following fertilization, 
and then visualized live under a Leica SPE confocal microscope. The absence (A) 
and thinning (B) of intersegmental blood vessels, as indicated by the white arrows, 
is randomly distributed in zebrafish embryos after treatment with SWCNT-
thalidomide. Scale bar: 250 µm in (A) and 100 µm in (B). 
Abbreviation: SWCNT, single-walled carbon nanotubes.
Figure 7 Tumor xenograft model in zebrafish embryos. Zebrafish embryos have been 
microinjected with fluorescent-labeled SKOV3:pEGFP mammalian cells suspended in 
Matrigel. The microinjection was conducted through the perivitelline space between 
the yolk and the periderm, close to the developing SIVs. The injection site is indicated 
by bright view in (A) using a white arrow, green fluorescence in (B) indicates 
presence of fluorescent-labeled SKOV3:pEGFP mammalian cells after injection, 
red fluorescence in (C) indicates presence of RGD-SWCNT(Rh)-thalidomide after 
injection, and (D) is (B) and (C) merged together. Scale bar: 150 µm. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-
walled carbon nanotubes; Rh, rhodamine; EGFP, enhanced green fluorescent 
protein; SIVs, subintestinal vessels.
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absence and thinning of intersegmental blood vessels. Among 
the 20 thalidomide-SWCNT-treated embryos, 11 showed 
both absence and thinning of intersegmental blood vessels, 
three showed thinning of intersegmental blood vessels, and 
six did not show any effects. The intersegmental blood ves-
sels were normally patterned in the treated embryos, and 
the absence or thinning of intersegmental blood vessels 
was randomly distributed (indicated by white arrows in 
 Figure 6), showing depleted expression of the fli1a endothe-
lial marker. Except for inhibition on intersegmental blood 
vessel formation, deleterious effects were not observed on 
the general morphology of embryonic structures by 48 hours 
following fertilization (data not shown). When assessed at 
48 hours following fertilization, the treated embryos were 
both mobile and responsive to stimuli. These results confirm 
that thalidomide-SWCNT possess antiangiogenic activity 
against angiogenic vessel formation, and can be used for 
angiogenesis inhibition in zebrafish embryos.
Targeted antiangiogenesis therapy using 
RGD-SWCNT(Rh)-thalidomide
The tumor xenograft model in zebrafish embryos used in this 
study is illustrated in Figure 7. The mammalian SKOV3 cells 
were transected with pEGFP, and stable SKOV3:pEGFP 
clones were resuspended in Matrigel and microinjected in 
the zebrafish embryos at 48 hours following fertilization 
(1000–2000 cells/embryo) through the perivitelline space 
between the yolk and the periderm (duct of Cuvier area), close 
to the developing subintestinal vessels (Figure 7A and B). 
Due to the immaturity of the immune system in zebrafish 
embryos until 48–72 hours following fertilization, no graft 
rejection occurred at this stage.28 The nanoconjugates for 
 antiangiogenesis, ie, RGD-SWCNT(Rh)-thalidomide, were 
simultaneously administrated at the same site (Figure 7C).
By imaging transgenic fli1a:EGFP zebrafish that contained 
fluorescently-labeled endothelial cells, tumor angiogenesis, 
including subintestinal vessel development, can be observed 
in transgenic zebrafish embryos under both fluorescent and 
confocal microscopy by checking the GFP signal. As shown in 
Figure 8, control embryos (Figure 8A) injected with Matrigel 
develop subintestinal vessels on the surface of the yolk in 
the shape of a basket. The use of proangiogenic tumor cell 
xenografts in zebrafish embryos allows continuous delivery 
of angiogenic factors produced by a limited number of tumor 
cells. The proangiogenic behavior of human HT1080 tumor 
cells is demonstrated in the xenografted zebrafish embryos. 
Figure 8 Blood vessels of transgenic fli1a:EGFP zebrafish embryos can be easily observed under the confocal microscope (A), and SIVs are marked by white arrows. 
Angiogenic responses (B and C) are triggered by tumor cell xenografts and targeted antiangiogenic therapy of RGD-SWCNT(Rh)-thalidomide (D, E and F) in transgenic 
fli1a:EGFP zebrafish embryos. Engraftment of human HT1080 fibrosarcoma cells, which secrete vascular endothelial growth factors, triggers ectopic angiogenesis of SIVs (B and 
C). Note morphological features of angiogenic response with engraftment of human HT1080 fibrosarcoma cells. When coinjected with RGD-SWCNT(Rh)-thalidomide (E), 
ectopic growth of angiogenesis of the SIV is obviously inhibited (D and F) in treated zebrafish embryos. White arrows (E and F) indicate presence of RGD-SWCNT(Rh)-
thalidomide after injection. (F) is the merge of (D) and (E). Scale bar: 200 µm. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-walled carbon nanotubes; Rh, rhodamine; EGFP, enhanced green fluorescent protein; SIVs, 
subintestinal vessels.
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As compared with the control embryos (Figure 8A), those 
injected with HT1080 cells (Figure 8B and C) show increased 
ectopic subintestinal vessel angiogenesis. Xenograftment of 
HT1080 cells induced an increase in the size of the area encom-
passed by the entire subintestinal vessel basket, as shown in 
Figure 8B. In some cases, xenograftment with proangiogenic 
mammalian HT1080 tumor cells induced the appearance of 
long spikes that project from the subintestinal vessel basket 
(long arrows), as shown in Figure 8C. Integrin α
v
β
3
 is highly 
expressed on activated endothelial cells, and the cyclic RGD 
peptide recognizes α
v
β
3
 integrin receptors. Here, RGD-labeled 
nanoconjugates specifically targeted the angiogenesis site in 
the subintestinal vessel area, and the coated antiangiogenic 
drug, thalidomide, inhibited ectopic angiogenesis. As shown 
in Figure 8D and F, 1.6 ng of modified thalidomide (red signal 
in Figure 8E, with 4.8 ng of SWCNT and 0.6 ng RGD) had 
an obvious angiogenesis inhibition effect on loaded zebrafish 
embryos. Furthermore, existing normal blood vessels, such as 
the subintestinal vessels, were not affected by administration 
of the nanoconjugates. No deaths were observed during any 
of the treatments.
The extent of inhibition efficacy using RGD-SWCNT(Rh)-
thalidomide varies in different embryos. Overall basket area 
and total vessel length within the subintestinal vessel basket 
area were quantified using the NIH Image program. As shown 
in Figure 9, in comparison with the control embryos, treat-
ment with proangiogenic HT1080 tumor cells increased the 
subintestinal vessel growth by increasing both subintestinal 
vessel area and total subintestinal vessel length. Treatment 
with RGD-SWCNT(Rh)-thalidomide reduced ectopic sub-
intestinal vessel growth, as shown in Figure 9, by reducing 
both subintestinal vessel area and total subintestinal vessel 
length. The inhibition efficacy of thalidomide-SWCNT(Rh)-
RGD nanoconjugates was also affected by its loading site and 
distribution profile. When loading was limited to the xeno-
graft site, ectopic angiogenesis of the subintestinal vessel was 
reduced (Figure 8D and E). When the distribution profile was 
expanded to whole embryos, including the whole yolk area 
and the circulation system, subintestinal vessel development 
was completely inhibited (data not shown).
Discussion
The potential for toxic effects of drugs and difficulty in limit-
ing drug uptake are major considerations for most delivery 
systems. Administration by incubating zebrafish embryos in a 
drug solution is not able to control the drug uptake and thus the 
effect will be systemic, but not local. Administration by injec-
tion can reduce the drug amount and improve drug uptake in a 
desired location. However, administration by injection without 
targeting can potentially induce systemic toxic effects. Admin-
istering drugs by conjugation to a multimodal drug vector can 
combine the drugs together with the targeting molecules, thus 
improving drug uptake and minimizing side effects.
Functionalized carbon nanotubes are an emerging nano-
vector for the delivery of therapeutics, and functionaliza-
tion strategies are a key step for the integration of carbon 
nanotubes into different systems for potential applications. 
Many functionalization strategies have been investigated 
for  multimodal drug delivery. Previous studies have dem-
onstrated that carbon nanotubes can be functionalized with 
two different molecules, ie, a drug and a fluorescent probe.29 
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Figure 9 Total SIV length and area measurements in the zebrafish angiogenesis 
assay. The transgenic fli1a:EGFP zebrafish was used to study in vivo angiogenesis. 
By imaging live transgenic fli1a:EGFP zebrafish that contained fluorescently labeled 
endothelial cells at 72 hours following fertilization, the blood vessels are visualized 
under confocal microscopy. The total SIV vessel length and area is determined 
by using the NIH Image program. Each bar represents the mean ± standard 
deviation (n = 15). The control group refers to embryos injected with Matrigel 
only, the xenografted group refers to embryos xenografted with proangiogenic 
mammalian tumor cells HT1080, and the xenografted and treated group refers to 
embryos xenografted with proangiogenic tumor cells together with antiangiogenic 
nanotherapeutics RGD-SWCNT(Rh)-thalidomide. 
Abbreviations: RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-
walled carbon nanotubes; Rh, rhodamine; EGFP, enhanced green fluorescent 
protein; SIV, subintestinal vessel.
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SWCNT have also been functionalized with both oligonucle-
otides and a folate moiety to achieve selective cancer cell 
destruction.8 Recently, the triple functionalization strategy 
of SWCNT with a drug, targeting moiety, and fluorescent 
marker has also been developed for targeted cancer therapy.30 
In this work, we present a method for triple functionalization 
of SWCNT with three moieties on the surface to achieve 
targeted delivery of small doses of antiangiogenic drugs to 
newly formed blood vessels, and we have further assessed its 
efficacy in transparent zebrafish embryos. This work presents 
a new functionalization approach to equip purified SWCNT 
with three different agents for targeted drug delivery. The 
present methodology allows for targeted delivery of an 
antiangiogenic drug to tumor sites and visualization of the 
distribution of SWCNT by confocal microscopy. It is inter-
esting to note that all the molecules attached onto carbon 
nanotubes preserved their functions after the conjugation 
process. These findings indicate that carbon nanotubes, 
especially SWCNT, have considerable potential for improv-
ing drug delivery.
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Supplementary materials and 
methods
Preparation of thalidomide analogs 1–5
Thalidomide 1 100 mg (0.387 mmol) dissolved in 30 mL 
of dry DMF were added to sodium hydride (60%, 25 mg, 
0.625 mmol) and stirred for 30 minutes. 2-(Boc-amino) 
ethyl bromide (130 mg, 0.58 mmol) was then added into 
the solution. The mixture was stirred at room temperature 
for 12 hours. The resulting mixture was extracted with 
ethyl acetate (30 mL × 3), the organic layer was washed 
with saturated NaCl and dried (anhydrous Na
2
SO
4
), the 
solvent was evaporated under reduced pressure to afford 
thalidomide 2. 1H NMR (CDCl
3
, 300 mHz) δ 7.78–7.83 
(m, 2H, ArH), 7.67–7.72 (m, 2H, ArH), 4.88–4.96 (m, 1H, 
CH), 3.92–3.95 (m, 2H, NCH
2
CH
2
NH), 3.24–3.29 (m, 2H, 
NCH
2
CH
2
NH), 1.36 [s, 9H, C(CH
3
)
3
]: An analytical sample 
was obtained by silica column chromatography eluted with 
CH
3
Cl. Compound 2 was then treated by trifluoroacetic 
acid in dichloromethane (CH
2
Cl
2
) for 4 hours to remove 
protective BOC groups. The solvent was evaporated under 
reduced pressure to afford 3. 1H NMR (MeOD, 300 mHz) 
δ 7.85–7.93 (m, 4H, ArH), 5.18–5.25 (dd, J
1
 = 5.70 Hz, 
J
2
 = 12.75 Hz, 1H, CH), 4.10–4.15 (m, 2H, NCH
2
CH
2
NH), 
3.12–3.17 (m, 2H, NCH
2
CH
2
NH). Then the compound 
3 was conjugated with S-acetylthioglycolic acid N-hy-
droxysuccinimide ester for 2 hours to obtain compound 4 
(MS-ESI m/z (relative intensity): 440.4 (100%),  followed 
by thiol deprotection using hydroxylamine under neutral 
conditions to yield the thiolated thalidomide 5 (MS-
ESI m/z [relative intensity]: 375.4) (100%), denoted as 
thalidomide-SH.
Abbreviations: DMF, dimethylformamide; NMR, nuclear 
magnetic resonance; MS, mass spectroscopy; ESI, electro-
spray ionization.
Synthesis of functionalized SWCNT
A Preparation of PEGylated single-walled  
carbon nanotubes (SWCNT)
2. Raw SWCNT were first oxidized to obtain oxidized 
SWCNT 1. Raw SWNT 50 mg were oxidized to yield a 
functionalized SWCNT 1 using 50 mL of concentrated HNO
3
 
by sonicating for 1 hour, followed by heating at 100°C for 
24 hours. The reaction mixture diluted to 500 mL with water 
was filtered through a polycarbonate filter (Whatman, pore 
size 0.22 µm). The product was then washed thoroughly by 
water until the pH reached neutral conditions and further 
oven dried at 100°C under vacuum for 4 hours (40 mg, 80%). 
The oxidized SWCNT were then conjugated with PEG to 
get PEGylated SWCNT 2. A suspension of the oxidized and 
cut SWCNT (30 mg) in 0.1 M phosphate-buffered solution 
(pH = 7.4) were mixed with EDC 60 mg and PEG
3500N
 50 mg 
and sonicated for 24 hours to afford PEGylated SWCNT 2. 
The aqueous suspension was then centrifuged at 12,000 rpm 
for about 1 hour to remove any large unreacted SWCNT from 
O
O O
1 2
3
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O O
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Figure S1 Synthesis of thalidomide analogs. Reagents and conditions are the following: (a) 2-(Boc-amino) ethyl bromide, trifluoroacetic acid, room temperature, 12 hours; 
(b) trifluoroacetic acid in CH2Cl2, 4 hours; (c) SATA, phosphate-buffered saline, 2 hours; (d ) NH2OH, ethylenediamine tetra-acetic acid, phosphate-buffered saline.
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Figure S2 Synthesis route of SWCNT-FITC 7 and FITC-SWCNT-RGD 9 conjugates. (a) HNO3, 24 hours; (b) H2N-PEG-NH2, EDC, NHS, 0.1 M PBS, pH 7.4; (c) FITC, 
DMF, dark; (d) SMCC, DMSO; (e) RGD-SH, 0.1 M PBS.
Abbreviations: FITC, fluorescein isothiocyanate; RGD, cyclic arginine-glycine-aspartic peptide; SWCNT, single-walled carbon nanotubes; SMCC, succinimidyl 4-[N-
maleimidomethyl]cyclohexane-1-carboxylate; DMSO, dimethyl sulfoxide; PBS, phosphate-buffered solution; EDC, 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide; PEG, 
polyethylene glycol; DMF, dimethylformamide.
the solution. The resulting solution was then dialyzed against 
H
2
O in a 12,000–14,000 molecular weight cutoff mem-
brane (Spectro/Por dialysis tubing) for three days to yield 
PEGylated SWCNT-PEG-NH
2
. The resulting product was 
lyophilized overnight to give pure SWCNT-PEG-NH
2
.
Abbreviations: SWCNT, single-walled carbon nanotubes; 
EDC, 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide; 
PEG, polyethylene glycol.
B Synthesis of Rh-SWCNT
The PEGylated SWCNT dissolved in 0.1 M phosphate-buff-
ered solution was stirred overnight with NHS-Rh to afford 
Rh-SWCNT conjugates. The resulting solution was then 
dialyzed against H
2
O in a 12,000–14,000 molecular weight 
cutoff membrane to remove excess Rh reagents.
Abbreviations: SWCNT, single-walled carbon nanotubes; 
Rh, rhodamine; PEG, polyethylene glycol; NHS, N-hydroxy 
succinimide.
C Preparation of Rh-SWCNT-SMCC,  
Rh-SWCNT-RGD and RGD-SWCNT(Rh)-
thalidomide nanoconjugates
20 mg of SMCC in 2 mL of DMSO was added to a solution 
of Rh-SWCNT (5 mL) in 0.1 M phosphate-buffered solution 
(supplemented with 0.3 M NaCl, pH = 7.4). The mixture was 
allowed to react at room temperature for 2 hours, after which 
the conjugate was dialyzed against H
2
O to remove excess 
SMCC linkers. For a preparation of RGD-SWCNT(Rh)-
thalidomide conjugate, Rh-SWCNT-SMCC solution was 
concentrated by using a centrifugal device (10,000 or 30,000), 
and the volume was reduced to 5 mL. Then Rh-SWCNT-
SMCC conjugate 4 was reacted overnight with RGD-SH and 
thalidomide-SH in the presence of 10 mM Tris(2-carboxy-
ethyl)phosphine hydrochloride at pH 7.4. Excess RGD-SH 
and thalidomide-SH was removed by dialysis, in the same 
manner as that described above, to yield RGD-SWCNT(Rh)-
thalidomide and Rh-SWCNT-RGD conjugates.
The amount of RGD on SWCNT was estimated by 
bicinchoninic acid protein assay. We assumed that the 
concentration of SWCNT on Rh-SWCNT and RGD-
SWCNT(Rh)-thalidomide are the same. The enzyme-linked 
immunosorbent assay at 470 nm was performed on RGD-
SWCNT(Rh)-thalidomide, RGD (as a positive control), and 
SWCNT(Rh) + RGD (as a negative control) with various 
concentrations to establish calibration curves. Therefore, the 
loading of RGD on SWCNT was calculated from a calibra-
tion curve of Rh-SWCNT + RGD conjugates. The amount 
of RGD on SWCNT was 0.125 mg/mg. Ultraviolet-visible 
measurement was carried out using a spectrophotometer. 
Concentration of thalidomide loaded onto the SWCNT was 
measured by the absorbance peak at 299 nm (characteristic of 
thalidomide). We assumed that the concentration of SWCNT 
on Rh-SWCNT and RGD-SWCNT(Rh)-thalidomide are 
the same. The ultraviolet-visible measurement of Rh-SW-
CNT + RGD at various concentrations was performed to 
establish calibration curves. The concentration of thalidomide 
on SWCNT was estimated to be 0.334 mg/mg.
Abbreviations: RGD, cyclic arginine-glycine-aspartic 
peptide; SWCNT, single-walled carbon nanotubes; Rh, 
rhodamine; SMCC, succinimidyl 4-[N-maleimidomethyl]
cyclohexane-1-carboxylate; DMSO, dimethyl sulfoxide.
D Synthesis of FITC-SWCNT and FITC-SWCNT-
RGD (Scheme S2)
The PEGylated SWCNT in 10 mL of 0.1 M phosphate-
buffered solution (pH 8.0) was added a solution of FITC in 
DMF (18 mg, 0.046 mmol). The mixture was then stirred 
overnight at room temperature. The resulting solution was 
then dialyzed against H
2
O in a 12,000–14,000 molecular 
weight cutoff membrane to remove free FITC. Then, 20 mg 
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of SMCC in 2 mL of DMSO was added to a solution of 
SWCNT-FITC (5 mL) in 0.1 M phosphate-buffered solution 
(supplemented with 0.3 M NaCl, pH = 7.4). Excess SMCC 
was removed by dialysis to yield FITC-SWCNT-SMCC. 
RGD-SH was added into FITC-SWCNT-SMCC in 2 mL 
0.1 M phosphate-buffered solution. The resulting suspen-
sion was stirred overnight at room temperature. Unreacted 
RGD-SH was removed by dialysis, in the same manner as 
that described above.
Abbreviations: FITC, fluorescein isothiocyanate; RGD, 
cyclic arginine-glycine-aspartic peptide; SWCNT, single-
walled carbon nanotubes; Rh, rhodamine; SMCC, succin-
imidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate; 
DMSO, dimethyl sulfoxide, DMF, dimethylformamide.
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